London, 15 May 2025 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, is today hosting sell-side analysts and investors at its US manufacturing and R&D facility in Columbus, Ohio. The senior leadership teams from our Generics and Injectables segments will present on their respective businesses, strategies, and plans to deliver long-term, sustainable growth.

Attendees will tour the Group's state-of-the-art, 1,000,000 sq. ft. facility in Columbus, which produces oral, respiratory and other generic and specialty products. It is one of Hikma's four US manufacturing facilities producing a broad range of medicines for patients across the US, where Hikma is one of the largest suppliers of generic medicines. Attendees will also tour the Company's newly acquired Injectables facility in Bedford, Ohio.

Alongside the event, Hikma is introducing the following medium-term guidance:

• Group revenue growth - 6% to 8% three-year CAGR (2024 to 2027)
• Group core operating profit growth - 7% to 9% three-year CAGR (2024 to 2027)

In addition, Hikma is introducing a five-year target for Group revenue to reach $5 billion by 2030.

Hikma is also announcing that its Generics business is being renamed Hikma Rx to reflect its focus on providing differentiated and complex prescription (Rx) medicines.

The presentation is available on Hikma's website at https://www.hikma.com/investors/results-and-presentations/. A recording and transcript of the presentation and Q&A will be made available following the event.